Sarclisa® (isatuximab) combination provides unprecedent

Latest results from the Phase 3 IKEMA clinical trial evaluating Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd) demonstrated a median progression free survival (mPFS) of 35.7 months (Hazard Ratio [HR] 0.58; 95% Confidence Interval [CI]: 25.8 to 44.0; n=179), compared to 19.2 months in ...

Related Keywords

France , Paris , France General , Kd Sarclisa , Peterc Adamson , Philippe Moreau , University Hospital Of Nantes , European Union , Drug Administration , Head Of The Department Hematology , Global Head Of Oncology Clinical Development , Controversies In Multiple Myeloma World Congress , European Society For Medical Oncology On , Hazard Ratio , Confidence Interval , Independent Review , Multiple Myeloma World Congress , European Society , Medical Oncology , University Hospital , Not Calculable , Oncology Clinical Development , Pediatric Innovation , Nonproprietary Naming , Biological Products Guidance ,